A Common Patient Assistance Program Application Form for HIV Medicine: Improved and Available

Cross-posted from AIDS.gov

NASTAD Common HIV Patient Assistance Program Application Form

A new streamlined application form is available to help low-income individuals who are living with HIV access antiretroviral (ARV) medicines through HIV patient assistance programs (PAPs).

Need for a Streamlined Application Form

PAPs are programs operated by pharmaceutical companies to provide free ARV medicines to low-income people living with HIV who do not qualify for insurance or assistance programs, such as Medicaid, Medicare, or AIDS Drug Assistance Programs (ADAPs). Each individual company has varying eligibility criteria. Most programs have a financial eligibility level of 500% of the Federal Poverty Level, or $57,450 for one person.  Some programs have lower eligibility levels, but many also make exceptions to their eligibility criteria based on the needs of individuals applying for their program. Eligibility levels and other criteria of PAPs can be found on the Positively Aware website or the Fair Pricing Coalition‘s website. Continue reading

After Five Years, ADAP Waiting Lists Have Been Eliminated

ADAP Watch No Waiting Lists November 2013After Five Years, ADAP Waiting Lists Have Been Eliminated; Unmet Need and Funding Uncertainties Require Continued Commitment

FOR IMMEDIATE RELEASE
Contact: Murray Penner
202-434-8090
mpenner@NASTAD.org

November 25, 2013, Washington, DC – According to NASTAD’s latest ADAP Watch, released today, there are no individuals on AIDS Drug Assistance Program (ADAP) waiting lists in the United States. This represents a significant milestone as there have been individuals on ADAP waiting lists since January 2008. The last state to have a waiting list, South Dakota, was able to transition the remaining 11 individuals on their waiting list into their ADAP program on November 21. Earlier this month, Alabama and Idaho eliminated their waiting lists and lifted their enrollment caps.  Continue reading

ADAP Crisis Task Force Announces Continued Partnership with Bristol-Myers Squibb and Boehringer Ingelheim for AIDS Drug Assistance Programs in the United States

FOR IMMEDIATE RELEASE
Contact: Murray Penner
202-434-8090
mpenner@NASTAD.org

ADAP AlertOctober 28, 2013, Washington, DC – The ADAP Crisis Task Force (Task Force) announced today that it has reached agreement with Bristol-Myers Squibb (BMS) and Boehringer Ingelheim (BI) to extend voluntary discounts/rebates and price freezes to all state AIDS Drug Assistance Programs (ADAPs).  The continuation of existing agreements beyond 2013 will provide stability to ADAPs as they continue to navigate the uncharted terrain of a reformed health system as a result of implementation of the Affordable Care Act (ACA) and continued fiscal challenges at both the state and federal level.

The Task Force, convened by the National Alliance of State and Territorial AIDS Directors (NASTAD), previously secured continuation through 2014 of existing agreements for voluntary discounts and rebates from AbbVie, Gilead Sciences, Janssen Therapeutics, Merck and ViiV Healthcare.  Many of these agreements also provide continued price freezes for ADAPs for varying lengths of time into 2014 and 2015.  Continue reading

It’s All Happening: Open Enrollment Is Here!

0 Days to Open EnrollmentBy Amy Killelea, Associate Director, Health Care Access, NASTAD

After a three and a half year wait – and several near-death experiences along the way – open enrollment under the Affordable Care Act (ACA) is finally here. On October 1st, 2013 the Marketplaces officially open for business, and millions of people will begin to apply for new public and private insurance coverage options.  At this point, we all know the incredible opportunities to expand HIV and viral hepatitis prevention, care, and treatment that are at stake. Now is where the rubber meets the road as federal, state, and local advocates, providers, and programs roll up their sleeves and prepare for full implementation. Below are four action items the HIV and viral hepatitis community should be focusing on as we leap into open enrollment and beyond: Continue reading

Update: Ryan White Program Current Status

By Ann Lefert, National Alliance of State and Territorial AIDS Directors and Bill McColl, AIDS United, Co-Chairs of the Ryan White Work Group, Federal AIDS Policy Partnership

Federal AIDS Policy Partnership (FAPP)As Co-Chairs of the Ryan White Work Group, we wanted to provide you with an update on the Ryan White Program. As you know, the current authorization ends on September 30, 2013.  However, there is no “sunset” provision in the legislation.  Therefore even if Congress does not take action, the Ryan White Program will remain a part of the law allowing funding to continue to be appropriated through the annual congressional appropriations process. Continue reading